Radioisotope imaging developer Molecular Insight Pharmaceuticals will proceed with phase III trials of its molecular imaging pharmaceutical, (123I)-BMIPP, for the visualization of cardiac metabolism. In its phase II trials, the firm said the uptake of (123I)-BMIPP in patients with ischemia provided evidence of an ischemic event up to 24 hours after its occurrence without the need of a stress test.
The current standard of assessing ischemia in patients presenting to the emergency department requires that resting perfusion imaging be performed within two hours after chest pain occurs.
The phase II data also confirm the previous findings of a phase I study performed at Massachusetts General Hospital in Boston that demonstrated the ability of (123I)-BMIPP to routinely deliver high-quality images of the heart, said the company.
By AuntMinnie.com staff writersSeptember 15, 2003
Copyright © 2003 AuntMinnie.com
